Clinical Trials Logo

Clinical Trial Details — Status: Unknown status

Administrative data

NCT number NCT02054845
Other study ID # CWO/13-05E
Secondary ID
Status Unknown status
Phase N/A
First received January 30, 2014
Last updated February 3, 2014
Start date January 2014
Est. completion date December 2014

Study information

Verified date February 2014
Source VU University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Approximately 60% of the patients with Parkinson's Disease (PD) that receive Levodopa therapy eventually develop response fluctuations in motor symptoms, such as rigidity, freezing and akinesia. Patients experience an 'off'-period just before the next dose of dopaminergic medication is needed, called the 'wearing-off'-phenomena. Wearing-off is also accompanied by non-motor symptoms such as depression, anxiety, pain and thinking disability. Together, these motor and non-motor symptoms have a major impact on the quality of life of patients and their partner or caregiver.

Patients with wearing-off often experience severe anxiety and panic symptoms that are incongruent with the severity of the motor symptoms during an 'off' period. These symptoms include stress, dizziness, pounding/racing of the heart, dyspnoea and hyperventilation. This type of anxiety is called wearing-off related anxiety (WRA) and might be a consequence of the hypersensitivity towards somatic manifestations and effects of a wearing-off period. This bodily misperception can have major consequences for the patient's feelings and behaviour. The experienced anxiety is often not consciously linked to the wearing-off and is therefore not well recognized by neurologists.

Treatment as usual in response fluctuations is physiotherapy, consisting of physical exercises for mobility problems, freezing, dyskinesias, etc. This kind of training hardly touches upon the mental aspects and the role of anxiety as integral element of the response fluctuations. Cognitive behaviour therapy (CBT, including exposure in vivo) is sometimes used to treat WRA, but seems to have unsatisfactory results since the changed body awareness is not sufficiently addressed. Also, the methods used in cognitive therapies focus on the elimination of WRA which is often not realistic since wearing-off symptoms will remain or even increase during disease progression. As of yet, there are no known alternative intervention options. This study focuses on a new intervention by integrating elements from physiotherapy, mindfulness, CBT (mainly exposure), Acceptance and Commitment Therapy (ACT) and psycho-education.

Objective: The current proposal aims at investigating the effect of a multidisciplinary non-verbal intervention on the awareness and modulation of WRA to improve self-efficacy, mobility, mood, and quality of life as compared to usual care.

Study design: Randomized controlled clinical trial.

Study population: Thirty-six PD patients who experience WRA.

Intervention: Patients with PD are randomly allocated into one of two groups (n= 18 each). One group receives the experimental 'body-awareness therapy', while the second group receives regular group-physiotherapy (treatment as usual). Both interventions will take 6 weeks in which 2 sessions per week with a duration of 1,5 hour will be performed.

Main study parameters/endpoints: The General Self-Efficacy Scale is the primary outcome measure and will be assessed prior to, directly after and 18 weeks after the intervention.


Recruitment information / eligibility

Status Unknown status
Enrollment 36
Est. completion date December 2014
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Clinical diagnosis of idiopathic Parkinson's Disease

- Experiencing Wearing-off

- Experiencing anxiety (BAI > 27)

Exclusion Criteria:

- Dementia (MMSE < 22)

- Other neurologic, orthopedic, cardiopulmonary problems that may interfere with participation

Study Design


Intervention

Behavioral:
Body awareness therapy
Experimental condition: BEWARE training group The physical and psychosocial elements of the training sessions will be complementary: psychological techniques are used to induce and endure wearing-off and physical techniques are used to improve body awareness to cope with the off-periods. Specifically the following techniques will be applied: Body scan Psychoeducation Acceptance Commitment Therapy / Mindfulness skills (sustained attention, concentration, non-reactivity, nonjudging of experience) Body Awareness Training Exposure training (imaginary exposure to induce response fluctuations) Training in cueing techniques to overcome problems with initiation and freezing Visual Feedback training Relaxation techniques
Other:
Physical therapy
Control condition: Treatment as Usual The control group will receive treatment as usual based on the current guidelines for physical therapy in patients with Parkinson's Disease, with the same training schedule of 2x per week for 1,5 hours during 6 weeks. Group treatment will contain exercises for balance, walking, posture, transfers, arm/hand dexterity, strength, flexibility, relaxation and physical condition.

Locations

Country Name City State
Netherlands VU Medical Center Amsterdam Noord-Holland

Sponsors (2)

Lead Sponsor Collaborator
VU University Medical Center Parkinsonvereniging

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Mental state To decide whether patients have to be excluded from the study, cognitive ability is measured with the Mini Mental State Examination (MMSE) baseline
Primary Self-efficacy how the patients can live their lives without being controlled by their disease, measured with the General Self Efficacy Scale Change from baseline in self-efficacy at 6 weeks
Primary Self-efficacy how the patients can live their lives without being controlled by their disease, measured with the General Self Efficacy Scale Change from baseline in self-efficacy at 18 weeks
Secondary Anxiety measured with the Beck Anxiety Inventory Change from baseline in anxiety at 6 weeks
Secondary Depression measured with the Beck Depression Inventory Change from baseline in depression at 6 weeks
Secondary Balance performance measured with the One Leg Stance test Change from baseline in balance performance at 6 weeks
Secondary comfortable walking speed measured with the 10 Meter Walk Test Change from baseline in walking speed at 6 weeks
Secondary Quality of life measured with the Parkinson's Disease Questionnaire - 39 Change from baseline in quality of life at 6 weeks
Secondary Wearing-off symptoms Assessing wearing-off related symptoms with the Wearing-off Questionnaire - 19 Change from baseline in wearing-off symptoms at 6 weeks
Secondary Activities of Daily Living independence measured with the Nottingham Extended Activities of Daily Living index Change from baseline in independence at 6 weeks
Secondary Freezing of Gait To asses an important symptom of Parkinson's disease, we included the Freezing of Gait Questionnaire Change from baseline in freezing of gait at 6 weeks
Secondary Anxiety measured with the Beck Anxiety Inventory Change from baseline in anxiety at 18 weeks
Secondary Depression measured with the Beck Depression Inventory Change from baseline in depression at 18 weeks
Secondary Balance performance measured with the One Leg Stance Test Change from baseline in balance performance at 18 weeks
Secondary Comfortable walking speed measured with the 10 Meter Walk Test Change from baseline in walking speed at 18 weeks
Secondary Quality of Life measured with the Parkinson's Disease Questionnaire - 39 Change from baseline in quality of life at 18 weeks
Secondary Wearing-off symptoms assessing wearing-off related symptoms with the Wearing-Off Questionnaire - 19 Change from baseline in anxiety at 6 weeks
Secondary Activities of Daily Living independence measured with the Nottingham Extended Activities of Daily Living index Change from baseline in independence at 18 weeks
Secondary Freezing of gait to assess an important symptom of Parkinson's Disease, as measured by the freezing of gait questionnaire Change from baseline in freezing of gait at 18 weeks